# CART-PSMA-TGFβRDN Cells for Castrate-Resistant Prostate Cancer

> **NCT03089203** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **University of Pennsylvania** · enrollment: 23 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **BIOLOGICAL:** CART-PSMA-TGFβRDN cells
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine

## Key facts

- **NCT ID:** NCT03089203
- **Lead sponsor:** University of Pennsylvania
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-03-08
- **Primary completion:** 2038-09-08
- **Final completion:** 2038-12-08
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2026-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03089203

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03089203, "CART-PSMA-TGFβRDN Cells for Castrate-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03089203. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*